CASI Pharmaceuticals (CASIF) Equity Income (2022 - 2025)

CASI Pharmaceuticals (CASIF) has reported Equity Income for 4 consecutive years, with -$48.1 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Equity Income fell 30.04% year-over-year to -$48.1 million; the trailing twelve-month figure through Dec 2025 stood at -$56.6 million (down 5.86% YoY), and the FY2025 full-year result was $2187.0 billion, up 83.94% from the prior year.
• Equity Income declined to -$48.1 million in Q4 2025 per CASIF's latest filing, from $4.4 million in the prior quarter.
• Across five years, Equity Income topped out at $4.4 million in Q3 2025 and bottomed at -$48.1 million in Q4 2025.
• Historically, Equity Income has averaged -$10.7 million across 4 years, with a median of -$5.9 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Equity Income slumped 527.28% in 2024, then soared 490.23% in 2025.
• Over 4 years, Equity Income stood at -$18.5 million in 2022, then jumped by 68.15% to -$5.9 million in 2023, then plunged by 527.28% to -$37.0 million in 2024, then tumbled by 30.04% to -$48.1 million in 2025.
• According to Business Quant data, Equity Income over the past three periods registered -$48.1 million, $4.4 million, and -$2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.